relapsed refractory multiple myeloma Archives

J&J’s Tecvayli-Darzalex Faspro combination approved for myeloma after MajesTEC-3 Phase 3 results

By Pallavi Madhiraju on March 6, 2026 Pharma & Biotech

FDA approves J&J’s teclistamab plus daratumumab for relapsed myeloma from second line. Analyse the MajesTEC-3 data, safety profile, and what this changes for treatment.

Starton Therapeutics advances STAR-LLD as delivery innovation in multiple myeloma

By Soujanya Ravi on February 19, 2026 Pharma & Biotech

Starton Therapeutics advances STAR-LLD in Phase 2a. Explore how continuous lenalidomide delivery could reshape multiple myeloma care.

Bristol Myers Squibb pushes CELMoD frontier as FDA accepts iberdomide NDA in relapsed multiple myeloma

By Pallavi Madhiraju on February 18, 2026 Pharma & Biotech

FDA accepts Bristol Myers Squibb’s iberdomide NDA for relapsed multiple myeloma. Find out what this CELMoD filing could change next.